OWD
JNCE

Osborn Williams & Donohoe’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Osborn Williams & Donohoe’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-2,800
Closed -$17K – 703
2019
Q1 		$17K Buy
+2,800
New +$13.5K ﹤0.01% 576

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Osborn Williams & Donohoe's JNCE Position: Q2 2019 in Review

Osborn Williams & Donohoe sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2019, closing a stake of 2,800 shares — an estimated $17K sold.

Osborn Williams & Donohoe first reported a position in JNCE in Q1 2019 and held it in 1 quarter. The position peaked at $17K in Q1 2019. 80 funds tracked by Wall St. Rank hold JNCE as of Q2 2019.

  • Osborn Williams & Donohoe reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Osborn Williams & Donohoe sold 2,800 Jounce Therapeutics, Inc. Common Stock shares in Q2 2019, an estimated $17K.
  • Osborn Williams & Donohoe first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2019 and held it in 1 quarter.
  • Osborn Williams & Donohoe's Jounce Therapeutics, Inc. Common Stock position peaked at $17K in Q1 2019.
  • 80 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2019.

Based on Osborn Williams & Donohoe's 13F filing for Q2 2019, filed 26 Jul 2019.